EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Flutamide therapy for carcinoma of the prostate



Flutamide therapy for carcinoma of the prostate



Southern Medical Journal 71(7): 798-801



In our three-year experience with the use of flutamide for the treatment of carcinoma of the prostate, 20 patients with previously untreated stage D carcinoma of the prostate were enrolled in a 12-week double-blind study. Seven patients received 1.5 gm of flutamide daily, seven patients received 0.75 gm of flutamide daily, and six patients received 1.0 mg of diethylstilbestrol daily. Two patients receiving flutamide did not complete the 12-week study. Six patients receiving flutamide and three patients receiving diethylstilbestrol had objective evidence of improvement. Of the patients receiving flutamide, 50% were alive at one year, and 43% were alive at two years. Three of the original 14 patients started on flutamide are alive at 36, 33, and 24 months. In addition, we continued clinical evaluation of flutamide as an open study, enrolling six other patients (four with stage D and two with stage C carcinoma of the prostate). All except one of these patients had received previous hormonal therapy. At present, four are still being followed up at 13, 15, 20 and 24 months, demonstrating that flutamide can give positive results to some patients whose condition is deteriorating despite diethylstilbestrol therapy.

(PDF 0-2 workdays service: $29.90)

Accession: 038940648

Download citation: RISBibTeXText

PMID: 78529



Related references

Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. Prostate 40(2): 105-114, 1999

Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma. European Urology 37(2): 218-222, 2000

Combination finasteride and flutamide in advanced carcinoma of the prostate: Effective therapy with minimal side effects. Journal of Urology 154(5): 1642-1646, 1995

Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. Prostate 40(2): 105-114, July 1, 1999

Effect of flutamide and flutamide plus castration on prostate size in patients with previously untreated prostate cancer. Urology 47(5): 713-718, 1996

Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy. American Journal of Clinical Oncology 13(6): 461-464, 1990

A potential flutamide-withdrawal prostate cancer cell model The growth of ARCaP cells stimulated by flutamide and repressed by flutamide-withdrawal. Journal of Urology 161(4 SUPPL ): 177, April, 1999

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma: Analysis of time to progression. Cancer 78(10): 2164-2169, 1996

Response of carcinoma of the prostate to withdrawal of flutamide. British Journal of Urology 73(5): 601-601, 1994

Flutamide in the treatment of metastatic carcinoma of the prostate. British Journal of Urology 53(2): 152-153, 1981

Flutamide in the treatment of advanced carcinoma of the prostate. Rozhledy V Chirurgii 64(11): 723-728, 1985

Use of flutamide in the treatment of carcinoma of the prostate stages C and D (T3-T4, Nx-N0, M0-M1 categories). Minerva Urologica E Nefrologica 38(1): 71-76, 1986

Examination of the change in plasma concentration of OH-flutamide in low-dose flutamide (250 mg/day) monotherapy for prostate cancer patients. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 31(3): 377-380, 2004

Novel flutamide regulated genes in the rat ventral prostate: differential modulation of their expression by castration and flutamide treatments. Asian Journal of Andrology 9(6): 801-808, 2007